Products and platform
We are currently developing drug candidates for the treatment of patients suffering from fibrotic diseases, as well as a platform for testing products in ophthalmology.
Drug candidates
We currently have a class of products in development for the treatment of fibrotic diseases. The first is 554-001, for patients suffering from idiopathic pulmonary fibrosis, for which H4 Orphan Pharma has just received a positive scientific advice for the start of Phase 2 studies in humans. The second is 554-002, for patients suffering from dry eye syndrome.
Ophthalmology platform
In collaboration with the University of Poitiers (PRéTI laboratory), we have created a joint laboratory called DED-Lab, the aim of which is to study and develop tissue models of the human eye in order to be able to test drug candidates or any molecule intended to be administered to the eye, without any animal experimentation. The project is funded by the French National Research Agency (ANR).